238 related articles for article (PubMed ID: 16113092)
1. Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy.
Bianco R; Troiani T; Tortora G; Ciardiello F
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S159-71. PubMed ID: 16113092
[TBL] [Abstract][Full Text] [Related]
2. Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy.
Morgillo F; Bareschino MA; Bianco R; Tortora G; Ciardiello F
Differentiation; 2007 Nov; 75(9):788-99. PubMed ID: 17608727
[TBL] [Abstract][Full Text] [Related]
3. Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies.
Viloria-Petit AM; Kerbel RS
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):914-26. PubMed ID: 14967451
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor pathway targeted therapy in patients with aerodigestive malignancies.
Patel JD
Curr Opin Oncol; 2006 Nov; 18(6):609-14. PubMed ID: 16988582
[TBL] [Abstract][Full Text] [Related]
5. Rational bases for the development of EGFR inhibitors for cancer treatment.
Bianco R; Gelardi T; Damiano V; Ciardiello F; Tortora G
Int J Biochem Cell Biol; 2007; 39(7-8):1416-31. PubMed ID: 17596994
[TBL] [Abstract][Full Text] [Related]
6. Resistance to epidermal growth factor receptor-targeted therapy.
Morgillo F; Lee HY
Drug Resist Updat; 2005 Oct; 8(5):298-310. PubMed ID: 16172017
[TBL] [Abstract][Full Text] [Related]
7. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
Tabernero J
Mol Cancer Res; 2007 Mar; 5(3):203-20. PubMed ID: 17374728
[TBL] [Abstract][Full Text] [Related]
8. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
Baselga J; Arteaga CL
J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
[TBL] [Abstract][Full Text] [Related]
9. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.
Ciardiello F; Tortora G
Clin Cancer Res; 2001 Oct; 7(10):2958-70. PubMed ID: 11595683
[TBL] [Abstract][Full Text] [Related]
10. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Jänne PA; Johnson BE
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
[TBL] [Abstract][Full Text] [Related]
11. Targeting the EGFR and the PKB pathway in cancer.
Klein S; Levitzki A
Curr Opin Cell Biol; 2009 Apr; 21(2):185-93. PubMed ID: 19216065
[TBL] [Abstract][Full Text] [Related]
12. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.
Mendelsohn J; Baselga J
J Clin Oncol; 2003 Jul; 21(14):2787-99. PubMed ID: 12860957
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.
Modjtahedi H; Essapen S
Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350
[TBL] [Abstract][Full Text] [Related]
14. Biology of interactions: antiepidermal growth factor receptor agents.
Harari PM; Allen GW; Bonner JA
J Clin Oncol; 2007 Sep; 25(26):4057-65. PubMed ID: 17827454
[TBL] [Abstract][Full Text] [Related]
15. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
Tortora G; Ciardiello F; Gasparini G
Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
[TBL] [Abstract][Full Text] [Related]
16. Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer.
Astsaturov I; Cohen RB; Harari P
Expert Rev Anticancer Ther; 2006 Sep; 6(9):1179-93. PubMed ID: 17020453
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor biology in head and neck cancer.
Kalyankrishna S; Grandis JR
J Clin Oncol; 2006 Jun; 24(17):2666-72. PubMed ID: 16763281
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer.
Heymach JV; Nilsson M; Blumenschein G; Papadimitrakopoulou V; Herbst R
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4441s-4445s. PubMed ID: 16857825
[TBL] [Abstract][Full Text] [Related]
19. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
Dassonville O; Bozec A; Fischel JL; Milano G
Crit Rev Oncol Hematol; 2007 Apr; 62(1):53-61. PubMed ID: 17324578
[TBL] [Abstract][Full Text] [Related]
20. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
John T; Liu G; Tsao MS
Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
